Results 231 to 240 of about 230,014 (291)

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden   +3 more
wiley   +1 more source

Shared spatial and temporal principles govern connectome dynamics across timescales. [PDF]

open access: yesProc Natl Acad Sci U S A
Alderson TH   +12 more
europepmc   +1 more source

Single-kidney transplantation with discarded partner kidney vs. Dual kidney transplantation: results from a national cohort study. [PDF]

open access: yesBMC Nephrol
Näf S   +14 more
europepmc   +1 more source

Geneva

open access: yes, 2005
openaire   +1 more source

Characterization of residual kidney function in chronic hemodialysis patients using plasma metabolomics. [PDF]

open access: yesSci Rep
Jaques DA   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy